G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage biopharmaceutical company whose drug development pipeline requires animal testing as a standard, mandated component of its preclinical research. The company's investigational therapies, including its lead oncology candidates, undergo safety and efficacy testing in animal models as part of the regulatory submission process to the FDA. This reliance on animal data is central to the company's business model of bringing new chemical entities to market.

While specific details of G1 Therapeutics' animal testing protocols are not publicly disclosed in the gathered evidence, the company operates within an industry sector where animal use is systematic and non-negotiable for regulatory approval. The absence of a publicly available animal welfare policy or commitment to alternative methods places the company's practices under the general catch-all for commercial animal exploitation in research.